Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Proprotein convertase subtilisin kexin type 9 ( PCSK 9) is an enzyme that impairs low‐density lipoprotein cholesterol ( LDL ‐C) clearance from the plasma by promoting LDL receptor degradation. Patients with familial hypercholesterolemia ( FH ) have reduced or absent LDL receptors and should therefore have elevated PCSK 9 levels. Methods and Results: Fasting lipograms and PCSK 9 levels were measured 51 homozygous FH ( HoFH ), 20 heterozygous FH ( HeFH ), and 20 normocholesterolemic control subjects. Levels were repeated following high‐dose statin therapy. LDL ‐C levels were significantly higher in untreated HoFH (13.4±0.7 mmol/L) and HeFH patients (7.0±0.2 mmol/L) compared with controls (2.6±0.1 mmol/L) ( P <0.01). Statin therapy decreased LDL ‐C levels from 13.4±0.7 to 11.1±0.7 mmol/L in HoFH and from 7.0±0.2 to 3.6±0.2 mmol/L in HeFH patients ( P <0.01). PCSK 9 levels were higher in untreated HoFH (279±27 ng/mL) and HeFH (202±14 ng/mL) than in controls (132±10 ng/mL) (both P <0.01). High‐dose statin therapy increased PCSK 9 levels from 279±27 to 338±50 ng/mL in HoFH , and significantly so in the HeFH patients from 202±14 to 278±20 ng/mL ( P <0.01). Linear regression analysis showed a correlation between PCSK 9 and LDL ‐C (r=0.6769; P <0.0001); however, this was eliminated following statin therapy (r=0.2972; P =0.0625). Conclusions: PCSK 9 levels are elevated in untreated FH patients, particularly in those with HoFH . High‐dose statin therapy further increases PCSK 9 levels. PCSK 9 inhibitors might be a beneficial therapy for FH patients, even in those with HoFH .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 1×
““Loss-of-function” mutations decrease LDL receptor degradation and patients with these mutations have low LDL-C concentrations and appear to be protected from coronary heart disease.(10) Conversely, “gain-of-function” mutations accelerate LDL receptor degradation and carriers of these mutations present with elevated L…”
BackgroundMutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681 · cited 1×
“Secreted PCSK9 decreases the number of LDL receptors in hepatocytes, and in livers of parabiotic mice and knockout mice lacking PCSK9, there is an inverse relationship between PCSK9 expression and LDL receptor levels.(14,15) If the numbers of LDL receptors are reduced as occurs in HeFH and to a much greater extent in…”
BackgroundDecreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Molecular biology of PCSK9: its role in LDL metabolism
HORTON, J., COHEN, J., & HOBBS, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.12.008 · Cited by 621
Maxwell, K. N., & Breslow, J. L. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000162321.31925.a3 · Cited by 82 · cited 1×
“Over the past decade, however, FH has been linked to another gene that encodes the enzyme, proprotein convertase subtilisin kexin type 9 (PCSK9).(5,6) In general, the prevalence of PCSK9 mutations is very low compared with defects in the LDL receptor and Apo-B.”
Background
Cited by
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationPCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Lagace, T. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000114 · Cited by 372
Stein, E. A., Honarpour, N., Wasserman, S. M., Xu, F., Scott, R., & Raal, F. J. (2013) · Circulation · doi:10.1161/circulationaha.113.004678 · Cited by 300
Self-citationPCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Tavori, H., Fan, D., Blakemore, J. L., Yancey, P. G., Ding, L., Linton, M. F., & Fazio, S. (2013) · Circulation · doi:10.1161/circulationaha.113.001592 · Cited by 178
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Hagiwara, N., Kawada-Watanabe, E., Koyanagi, R., Arashi, H., Yamaguchi, J., Nakao, K., Tobaru, T., Tanaka, H., Oka, T., Endoh, Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx162 · Cited by 136
“This limits the effectiveness of statin therapy.(14) In addition, most hyperlipidaemic patients will remain under treatment for years, and although lipids should be measured regularly to assess therapeutic response, such assessment is not always continued over the long term.”
Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs · doi:10.1007/s40265-019-01114-z · Cited by 132
Lipid lowering therapy and circulating PCSK9 concentration
Nozue, T. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17012 · Cited by 127
Tavori, H., Rashid, S., & Fazio, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.017 · Cited by 86
“familial hypercholesterolemia (FH), heterozygotes and to a greater extent homozygotes, show significantly higher levels of plasma PCSK9 compared with normo-cholesterolemic controls (26), suggesting that the loss of the receptor LDL-binding function may also impair the clearance of PCSK9 from the circulation.”
Somanathan, S., Jacobs, F., Wang, Q., Hanlon, A. L., Wilson, J. M., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.115.304008 · Cited by 54
Gadkar, K., Budha, N., Baruch, A., Davis, J. D., Fielder, P., & Ramanujan, S. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.47 · Cited by 48
PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
Strøm, T. B., Tveten, K., & Leren, T. P. (2014) · Biochemical Journal · doi:10.1042/bj20130930 · Cited by 48
Susan-Resiga, D., Girard, E., Kiss, R. S., Essalmani, R., Hamelin, J., Asselin, M.-C., Awan, Z., Butkinaree, C., Fleury, A., Soldera, A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769430 · Cited by 35
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
“This LDLR-mediated effect on PCSK9 levels also occurs in humans, where PCSK9 levels are lowest in normolipidemic patients, higher in hypercholesterolemic patients with heterozygous familial hypercholesterolemia, and highest in homozygous familial hypercholesterolemia (HoFH) patients [59].”
BackgroundSasaki, M., Terao, Y., Ayaori, M., Uto-Kondo, H., Iizuka, M., Yogo, M., Hagisawa, K., Takiguchi, S., Yakushiji, E., Nakaya, K., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302670 · Cited by 28
Bjornsson, E., Gunnarsdottir, K., Halldorsson, G. H., Sigurdsson, A., Arnadottir, G. A., Jonsson, H., Olafsdottir, E. F., Niehus, S., Kehr, B., Sveinbjörnsson, G., et al. (2021) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.120.003029 · Cited by 23
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
Tavori, H., Melone, M., & Rashid, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.954551 · Cited by 21
“It has been recently reported that homozygous FH patients have higher PCSK9 levels than heterozygotes, who in turn have higher levels than controls [39].”
Background
Metadata
- Authors
- Raal, F., Panz, V., Immelman, A., & Pilcher, G.
- Venue
- Journal of the American Heart Association
- Published
- 2013-03-12
- Volume
- 2
- Issue
- 2
- Pages
- e000028-e000028
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2157115489
- Cited by
- 132
- References
- 9
- FWCI
- 17.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.